Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes.
Sign Up to like & getrecommendations! Published in 2020 at "Kidney international"
DOI: 10.1016/j.kint.2020.04.051
Abstract: Canagliflozin reduced kidney disease progression in participants with type 2 diabetes in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program that explored potential mediators of the effects of canagliflozin on kidney outcomes. The percent mediating effect… read more here.
Keywords: effects canagliflozin; effect; canagliflozin kidney; type diabetes ... See more keywords